19164557 |
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Quenzer, T,
Emmett, MR,
Deshmukh, GD,
Lunney, EA,
English, JM,
Wu, JC,
Christensen, J,
Molina, D,
He, YA,
Zhang, Y,
Greig, MJ,
Demetri, GD,
Yu, X,
Diehl, W,
McTigue, M,
Gajiwala, KS,
DiNitto, JP,
Wells, PA,
Jacques, SL,
Zou, A,
Zhang, HM,
Marshall, AG
|
Proc. Natl. Acad. Sci. U.S.A. |
2009 |
30792533 |
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Heinrich, MC,
Ketzer, J,
Bauer, S,
Zhu, M,
Presnell, A,
Raut, CP,
George, S,
Mannan, AM,
Serrano, C,
Yu, C,
Sicinska, E,
Tao, DL,
Rubin, BP,
Fletcher, JA,
Mariño-Enríquez, A,
Demetri, GD,
Eilers, G,
Czaplinski, JT,
McKinley, A
|
Br. J. Cancer |
2019 |
27030078 |
Immunological off-target effects of imatinib
Rusakiewicz, S,
Ayyoub, M,
Zitvogel, L,
Routy, B,
Kroemer, G
|
Nat Rev Clin Oncol |
2016 |
12181401 |
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Joensuu, H,
Silberman, SL,
Capdeville, R,
Peng, B,
Heinrich, MC,
Singer, S,
Roberts, PJ,
Blanke, CD,
von Mehren, M,
Eisenberg, B,
Fletcher, JA,
Demetri, GD,
Kiese, B,
Corless, C,
Silverman, SG,
Fletcher, CD,
Druker, BJ,
Janicek, M,
Dimitrijevic, S,
Tuveson, DA,
Van den Abbeele, AD
|
N. Engl. J. Med. |
2002 |